Analgesic and nonsteroidal anti-inflammatory use in relation to nonmelanoma skin cancer: a population-based case-control study.

[1]  Robin B Harris,et al.  Effect of non‐steroidal anti‐inflammatory drugs on non‐melanoma skin cancer incidence in the SKICAP‐AK trial , 2009, Pharmacoepidemiology and drug safety.

[2]  Alexei Vazquez,et al.  The genetics of the p53 pathway, apoptosis and cancer therapy , 2008, Nature Reviews Drug Discovery.

[3]  J. Fraumeni,et al.  Cancer epidemiology and prevention. , 2006 .

[4]  M. Karagas,et al.  Effect of NSAIDs on the recurrence of nonmelanoma skin cancer , 2006, International journal of cancer.

[5]  M. Karagas,et al.  Allelic loss at Drosophila patched gene is highly prevalent in Basal and squamous cell carcinomas of the skin. , 2006, The Journal of investigative dermatology.

[6]  Jeannette Bigler,et al.  Non-steroidal anti-inflammatory drugs for cancer prevention: promise, perils and pharmacogenetics , 2006, Nature Reviews Cancer.

[7]  D. Whiteman,et al.  Nonsteroidal anti-inflammatory drugs and the risk of actinic keratoses and squamous cell cancers of the skin. , 2005, Journal of the American Academy of Dermatology.

[8]  Y. Lou,et al.  Patches of mutant p53-immunoreactive epidermal cells induced by chronic UVB Irradiation harbor the same p53 mutations as squamous cell carcinomas in the skin of hairless SKH-1 mice. , 2005, Cancer research.

[9]  F. Pontén,et al.  Genetic tumor archeology: microdissection and genetic heterogeneity in squamous and basal cell carcinoma. , 2005, Mutation research.

[10]  E. van Marck,et al.  Cyclooxygenase‐2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases , 2004, The British journal of dermatology.

[11]  N. Swanson,et al.  Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze). , 2004, Journal of drugs in dermatology : JDD.

[12]  L. Magnelli,et al.  Down-regulation of nitric oxide synthase-2 and cyclooxygenase-2 pathways by p53 in squamous cell carcinoma. , 2003, The American journal of pathology.

[13]  G. Varigos,et al.  Topical diclofenac in hyaluronan gel for the treatment of solar keratoses , 2003, The Australasian journal of dermatology.

[14]  D. Alberts,et al.  Inhibitory effects of sodium salicylate and acetylsalicylic acid on UVB-induced mouse skin carcinogenesis. , 2002, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[15]  N. V. Chandrasekharan,et al.  COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: Cloning, structure, and expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Bale,et al.  The hedgehog pathway and basal cell carcinomas. , 2001, Human molecular genetics.

[17]  N. Altorki,et al.  Inhibition of Cyclooxygenase-2 Gene Expression by p53* , 1999, The Journal of Biological Chemistry.

[18]  J. Louhelainen,et al.  Dinucleotide repeat polymorphism within the tumor suppressor gene PTCH at 9q22 , 1998, Clinical genetics.

[19]  D. McLean,et al.  An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. , 1997, Archives of dermatology.

[20]  A. Kopf,et al.  Lifetime risk for development of skin cancer in the U.S. population: current estimate is now 1 in 5. , 1996, Journal of the American Academy of Dermatology.

[21]  C. Tabin,et al.  Biochemical evidence that Patched is the Hedgehog receptor , 1996, Nature.

[22]  J. Maclouf,et al.  Cyclooxygenases in human and mouse skin and cultured human keratinocytes: association of COX-2 expression with human keratinocyte differentiation. , 1996, Experimental cell research.

[23]  Bruce K. Armstrong,et al.  Sun exposure and non-melanocytic skin cancer , 1994, Cancer Causes & Control.

[24]  R. Weichselbaum,et al.  Mutation spectrum of the p53 gene in bone and soft tissue sarcomas. , 1992, Cancer research.

[25]  D. English,et al.  Pigmentary and cutaneous risk factors for non‐melanocytic skin cancer—A case‐control study , 1991, International journal of cancer.

[26]  Robert J. Gorlin,et al.  Nevoid Basal‐Cell Carcinoma Syndrome , 1987, Medicine.

[27]  V. Samarasinghe,et al.  Nonmelanoma Skin Cancer , 2012, Journal of cutaneous and aesthetic surgery.

[28]  S. Fischer.  Is cyclooxygenase-2 important in skin carcinogenesis? , 2002, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.